Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "RMD Open"
DOI: 10.1136/rmdopen-2018-000692
Abstract: Objective To conduct subset analyses of SPIRIT-P2 (NCT02349295) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying… read more here.
Keywords: psoriatic arthritis; active psoriatic; response; patients active ... See more keywords
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2021-002049
Abstract: Objective Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA; SELECT-AXIS 1 for AS). Methods… read more here.
Keywords: effect upadacitinib; patients active; psoriatic arthritis; active psoriatic ... See more keywords